Appendix Table 2.
Baseline Clinical Characteristics of Participants With Anemia at Study Entry Who Were Randomly Assigned to Receive Placebo or Canakinumab
| Characteristic | Placebo (n = 433) | Canakinumab | |||
|---|---|---|---|---|---|
| 50 mg (n = 260) | 150 mg (n = 294) | 300 mg (n = 316) | All Doses (n = 870) | ||
| Median age (IQR), y | 66.0 (58.0-73.0) | 65.0 (56.5-72.0) | 65.0 (57.0-72.0) | 65.0 (57.0-73.0) | 65.0 (57.0-72.0) |
| Female, n (%) | 138 (31.9) | 76 (29.2) | 81 (27.6) | 119 (37.7) | 276 (31.7) |
| Median hemoglobin level(IQR), g/L | 119 (112-126) | 119 (114-126) | 119 (113-126) | 118 (111-125) | 119 (113-126) |
| Median BMI (IQR), kg/m2 | 28.4 (25.3-33.3) | 29.1 (25.6-33.3) | 29.6 (26.2-34.4)* | 29.1 (24.8-34.2) | 29.3 (25.5-33.9) |
| Alcohol use (>1 drink per day), n (%) | 6 (1.39) | 11 (4.23)* | 5 (1.70) | 10 (3.16) | 26 (2.99) |
| Hypertension, n (%) | 368 (85.0) | 226 (86.9) | 243 (82.7) | 257 (81.3) | 726 (83.4) |
| Type 2 diabetes mellitus, n (%) | 221 (51.0) | 127 (48.8) | 165 (56.1) | 158 (50.0) | 450 (51.7) |
| Median hsCRP level (IQR), mg/L | 5.50 (3.10-10.4) | 5.65 (3.18-10.2) | 5.78 (3.40-10.7) | 5.78 (3.25-11.5) | 5.70 (3.25-10.7) |
| Median eGFR (IQR), mL/min/1.73 m2 | 69.0 (53.0-88.0) | 69.5 (52.0-85.5) | 71.0 (56.0-86.0) | 69.5 (51.5-89.0) | 70.0 (54.0-86.0) |
| Heart failure, n (%) | 129 (29.8) | 79 (30.4) | 84 (28.6) | 91 (28.8) | 254 (29.2) |
BMI = body mass index; eGFR = estimated glomerular filtration rate; hsCRP = high-sensitivity C-reactive protein; IQR = interquartile range.
*
P < 0.050 for the comparison of canakinumab with placebo.